Sero-Prevalence and Cross-Reactivity of Chikungunya Virus Specific Anti-E2EP3 Antibodies in Arbovirus-Infected Patients

PLoS Neglected Tropical Diseases

Volumn 9, Issue 1, 2015, Pages

  Kam, Yiu Wing ^a   Pok, Kwoon Yong ^b   Eng, Kai Er ^a   Tan, Li Kiang ^b   Kaur, Simrandeep ^b   Lee, Wendy W L ^a,c   Leo, Yee Sin ^d   Ng, Lee Ching ^b   Ng, Lisa F P ^a,e  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL ENVIRONMENT AGENCY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d TAN TOCK SENG HOSPITAL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI E2EP3 ANTIBODY; ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; VIRAL PROTEIN; VIRUS ANTIBODY;

ANIMAL CELL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARBOVIRUS; ARTICLE; BARMAH FOREST VIRUS; CHIKUNGUNYA ALPHAVIRUS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DENGUE VIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLAVIVIRUS; IMMUNOFLUORESCENCE TEST; IMMUNOREACTIVITY; LONGITUDINAL STUDY; NONHUMAN; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ROSS RIVER ALPHA VIRUS; SEROPREVALENCE; VIRUS INFECTION; VIRUS NEUTRALIZATION; BLOOD; CHIKUNGUNYA VIRUS; EPIDEMIOLOGY; HUMAN; IMMUNOLOGY; VIROLOGY;

ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ARBOVIRUS INFECTIONS; BIOMARKERS; CHIKUNGUNYA VIRUS; CROSS REACTIONS; HUMANS; IMMUNOGLOBULIN G; SEROEPIDEMIOLOGIC STUDIES; VIRAL PROTEINS;

EID: 84922231857     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003445     Document Type: Article

References (50)

1. Sun Y, Yan J, Mao H, Zhang L, Lyu Q, et al. (2013) Characterization of the complete genome of chikungunya in Zhejiang, China, using a modified virus discovery method based on cDNA-AFLP. PLoS One 8: e83014.
2. Chusri S, Siripaitoon P, Silpapojakul K, Hortiwakul T, Charernmak B, et al. (2014) Kinetics of Chikungunya Infections during an Outbreak in Southern Thailand, 2008-2009. Am J Trop Med Hyg 90: 410–417.
3. Chen KC, Kam YW, Lin RT, Ng MM, Ng LF, et al. (2013) Comparative analysis of the genome sequences and replication profiles of chikungunya virus isolates within the East, Central and South African (ECSA) lineage. Virol J 10: 169.
4. Schilte C, Staikowsky F, Couderc T, Madec Y, Carpentier F, et al. (2013) Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl Trop Dis 7: e2137.
5. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X, (2014) Chikungunya in the Americas. Lancet 383: 514.
6. Borgherini G, Poubeau P, Jossaume A, Gouix A, Cotte L, et al. (2008) Persistent arthralgia associated with chikungunya virus: a study of 88 adult patients on reunion island. Clin Infect Dis 47: 469–475.
7. Kam YW, Ong EK, Renia L, Tong JC, Ng LF, (2009) Immuno-biology of Chikungunya and implications for disease intervention. Microbes Infect 11: 1186–1196.
8. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, et al. (2013) Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100: 500–519.
9. Sambri V, Capobianchi M, Charrel R, Fyodorova M, Gaibani P, et al. (2013) West Nile virus in Europe: emergence, epidemiology, diagnosis, treatment, and prevention. Clin Microbiol Infect 19: 699–704.
10. Chang SF, Su CL, Shu PY, Yang CF, Liao TL, et al. (2010) Concurrent isolation of chikungunya virus and dengue virus from a patient with coinfection resulting from a trip to Singapore. J Clin Microbiol 48: 4586–4589.
11. Kumar KJ, Manjunath VG, Shailashree M, Girish GN, (2012) Coinfection with dengue and chikungunya—a case report. J Indian Med Assoc 110: 749–752.
12. Taraphdar D, Sarkar A, Mukhopadhyay BB, Chatterjee S, (2012) A comparative study of clinical features between monotypic and dual infection cases with Chikungunya virus and dengue virus in West Bengal, India. Am J Trop Med Hyg 86: 720–723.
13. Parreira R, Centeno-Lima S, Lopes A, Portugal-Calisto D, Constantino A, et al. (2014) Dengue virus serotype 4 and chikungunya virus coinfection in a traveller returning from Luanda, Angola, January 2014. Euro Surveill 19: 20730.
14. Lee VJ, Chow A, Zheng X, Carrasco LR, Cook AR, et al. (2012) Simple clinical and laboratory predictors of Chikungunya versus dengue infections in adults. PLoS Negl Trop Dis 6: e1786.
15. Pastorino B, Bessaud M, Grandadam M, Murri S, Tolou HJ, et al. (2005) Development of a TaqMan RT-PCR assay without RNA extraction step for the detection and quantification of African Chikungunya viruses. J Virol Methods 124: 65–71.
16. Edwards CJ, Welch SR, Chamberlain J, Hewson R, Tolley H, et al. (2007) Molecular diagnosis and analysis of Chikungunya virus. J Clin Virol 39: 271–275.
17. Santhosh SR, Parida MM, Dash PK, Pateriya A, Pattnaik B, et al. (2007) Development and evaluation of SYBR Green I-based one-step real-time RT-PCR assay for detection and quantification of Chikungunya virus. J Clin Virol 39: 188–193.
18. Grivard P, Le Roux K, Laurent P, Fianu A, Perrau J, et al. (2007) Molecular and serological diagnosis of Chikungunya virus infection. Pathol Biol (Paris) 55: 490–494.
19. Litzba N, Schuffenecker I, Zeller H, Drosten C, Emmerich P, et al. (2008) Evaluation of the first commercial chikungunya virus indirect immunofluorescence test. J Virol Methods 149: 175–179.
20. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, et al. (2012) Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol Med 4: 330–343.
21. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, et al. (2012) Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J Virol 86: 13005–13015.
22. Lum FM, Teo TH, Lee WW, Kam YW, Renia L, et al. (2013) An essential role of antibodies in the control of Chikungunya virus infection. J Immunol 190: 6295–6302.
23. Kam YW, Lee WW, Simarmata D, Le Grand R, Tolou H, et al. (2014) Unique epitopes recognized by antibodies induced in chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. PLoS One 9: e95647.
24. Tesh RB, Gajdusek DC, Garruto RM, Cross JH, Rosen L, (1975) The distribution and prevalence of group A arbovirus neutralizing antibodies among human populations in Southeast Asia and the Pacific islands. Am J Trop Med Hyg 24: 664–675.
25. Vazeille M, Moutailler S, Coudrier D, Rousseaux C, Khun H, et al. (2007) Two Chikungunya isolates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopictus. PLoS One 2: e1168.
26. Ayu SM, Lai LR, Chan YF, Hatim A, Hairi NN, et al. (2010) Seroprevalence survey of Chikungunya virus in Bagan Panchor, Malaysia. Am J Trop Med Hyg 83: 1245–1248.
27. Yap G, Pok KY, Lai YL, Hapuarachchi HC, Chow A, et al. (2010) Evaluation of Chikungunya diagnostic assays: differences in sensitivity of serology assays in two independent outbreaks. PLoS Negl Trop Dis 4: e753.
28. Duong V, Andries AC, Ngan C, Sok T, Richner B, et al. (2012) Reemergence of Chikungunya virus in Cambodia. Emerg Infect Dis 18: 2066–2069.
29. Nakkhara P, Chongsuvivatwong V, Thammapalo S, (2013) Risk factors for symptomatic and asymptomatic chikungunya infection. Trans R Soc Trop Med Hyg 107: 789–796.
30. Kosasih H, de Mast Q, Widjaja S, Sudjana P, Antonjaya U, et al. (2013) Evidence for endemic chikungunya virus infections in Bandung, Indonesia. PLoS Negl Trop Dis 7: e2483.
31. Reddy V, Mani RS, Desai A, Ravi V, (2014) Correlation of plasma viral loads and presence of Chikungunya IgM antibodies with cytokine/chemokine levels during acute Chikungunya virus infection. J Med Virol 86: 1393–1401.
32. Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, et al. (2010) Arboviral etiologies of acute febrile illnesses in Western South America, 2000–2007. PLoS Negl Trop Dis 4: e787.
33. Suhrbier A, Jaffar-Bandjee MC, Gasque P, (2012) Arthritogenic alphaviruses—an overview. Nat Rev Rheumatol 8: 420–429.
34. Hasebe F, Parquet MC, Pandey BD, Mathenge EG, Morita K, et al. (2002) Combined detection and genotyping of Chikungunya virus by a specific reverse transcription-polymerase chain reaction. J Med Virol 67: 370–374.
35. Morens DM, Halstead SB, Repik PM, Putvatana R, Raybourne N, (1985) Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22: 250–254.
36. Russell PK, Nisalak A, Sukhavachana P, Vivona S, (1967) A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99: 285–290.
37. Strauss JH, Strauss EG, (2001) Virus evolution: how does an enveloped virus make a regular structure? Cell 105: 5–8.
38. Bessoff K, Delorey M, Sun W, Hunsperger E, (2008) Comparison of two commercially available dengue virus (DENV) NS1 capture enzyme-linked immunosorbent assays using a single clinical sample for diagnosis of acute DENV infection. Clin Vaccine Immunol 15: 1513–1518.
39. Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, et al. (2008) Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya, October 2004. Am J Trop Med Hyg 78: 333–337.
40. Venugopalan A, Ghorpade RP, Chopra A, (2014) Cytokines in acute chikungunya. PLoS One 9: e111305.
41. Zhong W, Reed C, Blair PJ, Katz JM, Hancock K, (2014) Serum antibody response to matrix protein 2 following natural infection with 2009 pandemic influenza A(H1N1) virus in humans. J Infect Dis 209: 986–994.
42. Appassakij H, Khuntikij P, Kemapunmanus M, Wutthanarungsan R, Silpapojakul K, (2013) Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion 53: 2567–2574.
43. Ochsenbein AF, Fehr T, Lutz C, Suter M, Brombacher F, et al. (1999) Control of early viral and bacterial distribution and disease by natural antibodies. Science 286: 2156–2159.
44. Ochsenbein AF, Zinkernagel RM, (2000) Natural antibodies and complement link innate and acquired immunity. Immunol Today 21: 624–630.
45. Puga I, Cerutti A, (2013) Protection by natural IgG: a sweet partnership with soluble lectins does the trick! EMBO J. 32: 2897–2899.
46. Powers AM, Brault AC, Shirako Y, Strauss EG, Kang W, et al. (2001) Evolutionary relationships and systematics of the alphaviruses. J Virol 75: 10118–10131.
47. NovaTec Immunodiagnostica Gmbh. ELISA for CHKV antigen-specific IgG. Available: http://www.novatec-id.com/products/infectious-diseases/virology/chikungunya-new. Accessed 19 May 2014.
48. Mejias A, Hall MW, Ramilo O, (2013) Immune monitoring of children with respiratory syncytial virus infection. Expert Rev Clin Immunol 9: 393–395.
49. Netski DM, Mosbruger T, Depla E, Maertens G, Ray SC, et al. (2005) Humoral immune response in acute hepatitis C virus infection. Clin Infect Dis 41: 667–675.
50. Kam YW, Simarmata D, Chow A, Her Z, Teng TS, et al. (2012) Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J Infect Dis 205: 1147–1154.